3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
19
Carcinoma, Non-Small-Cell Lung
13
Breast Neoplasms
9
Neoplasms
6
Lung Neoplasms
5
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Breast Neoplasms, Male
4
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Fallopian Tube Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Oropharyngeal Neoplasms
2
Inflammatory Breast Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Solid Tumor
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Basal Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Interventions
neratinib
1
fludarabine
1
famitinib
1
encorafenib
1
camrelizumab
1
Valproic Acid
1
Taxes
1
TPI-287
1
Sodium Selenite
1
Nivolumab
1
Ifosfamide
1
Gemcitabine
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Disease Progression
×
Taxes
×
Clear all
NCT07049055
2026-02-27
Carolyn-USA
Engeneic Pty Limited
Phase 1/2
Recruiting
144 enrolled